Can I still use Atrasentan after taking it for three years?

Atrasentan (atrasentan) is a selective antagonist that acts on endothelinA receptor (ETA receptor). The safety of long-term use has always been the focus of attention of patients and clinicians. Based on overseas long-term observation data and pharmacological properties, atrasentan can be taken for a long time under strict monitoring. Its use for more than three years is theoretically feasible, but it requires continuous evaluation of the patient's renal function, liver function and cardiovascular status. Because this drug mainly improves renal microcirculation by regulating vasoconstriction and endothelial function, if the patient has water and sodium retention or mild heart failure during long-term use, appropriate dose reduction or intermittent discontinuation of the drug should be considered.

The significance of long-term use of atrasentan is that it can delay the decline of renal function. Unlike traditional therapies that only rely on blood sugar or blood pressure control, it intervenes in the glomerular injury response through molecular signaling pathways, so long-term maintenance therapy can achieve a more stable renal protection effect. However, long-term use does not mean indefinite use. Clinically, urine protein, serum creatinine and liver function indicators should be reviewed every three to six months, and the dosage should be adjusted according to changes in pharmacokinetics. Some guidelines recommend that after patients achieve stable renal function or a significant decrease in proteinuria, consideration may be given to extending the dosing interval or maintaining the lowest effective dose to reduce potential adverse reactions.

In terms of safety, the main adverse reactions of atrasentan include mild edema, decrease in blood pressure and weight gain, which can usually be alleviated after dose adjustment. There is currently no evidence that continuous use for more than three years will lead to severe systemic toxicity or obvious drug resistance. However, for elderly patients or those with heart failure, the burden on the heart and kidneys still needs to be carefully evaluated. With the progress of domestic marketing and the accumulation of real-world data, more conclusions will be drawn about its long-term efficacy and safety in the future.

Reference materials:https://www.vanrafia.com/